Study details
Enrolling now
Mitoquinone/mitoquinol mesylate for preventing COVID-19
University of Texas Southwestern Medical Center
NCT IDNCT05886816ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
112
Study length
about 2.4 years
Ages
18–65
Locations
1 site in TX
About this study
This trial is testing whether mitoquinone/mitoquinol mesylate (Mito-MES) can prevent the development of COVID-19 in adults after exposure to someone with SARS-CoV-2. Participants will receive either Mito-MES or a placebo, and it will last for 882 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Mitoquinone/mitoquinol mesylate
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Duration of symptoms of SARS-CoV-2 infection, Severity of symptoms of SARS-CoV-2 infection
Body systems
Infectious